1. Home
  2. LCFY vs XBIO Comparison

LCFY vs XBIO Comparison

Compare LCFY & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.30

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.15

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
XBIO
Founded
2009
N/A
Country
Australia
United States
Employees
18
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCFY
XBIO
Price
$4.30
$3.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.8K
14.2K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$1.90
52 Week High
$13.98
$13.93

Technical Indicators

Market Signals
Indicator
LCFY
XBIO
Relative Strength Index (RSI) 45.30 53.48
Support Level $4.07 $2.94
Resistance Level $4.84 $3.69
Average True Range (ATR) 0.19 0.15
MACD -0.05 -0.02
Stochastic Oscillator 23.53 52.38

Price Performance

Historical Comparison
LCFY
XBIO

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: